Stephen D. Griffin - 01 Feb 2026 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Reporting relationship: President and CEO, Director
Issuer ticker: ANIK
Reported as of: 01 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 18:45:54 UTC
Prior SEC filing: 05 Jun 2025
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen D. Griffin

Key filing fact

Stephen D. Griffin filed Form 4 for Anika Therapeutics, Inc. (ANIK) on 03 Feb 2026.

Key facts

This page summarizes Stephen D. Griffin's Form 4 filing for Anika Therapeutics, Inc. (ANIK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Feb 2026, 18:45.

Change

Previous filing in this sequence was filed on 05 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001831125 Primary reporting owner

Griffin Stephen D.

Relationship: President and CEO, Director
Address: 32 WIGGINS AVENUE, BEDFORD
Signature: /s/ Stephen D. Griffin
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,671
Date: 01 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANIK transaction Derivative

Stock Appreciation Rights

Award

Transaction value: $0
Shares: +310,207
Change %
Price: $0.000000
Shares after: 310,207
Date: 01 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 310,207
Exercise price: $9.23
Footnotes: F2, F3

ANIK transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +130,402
Change %
Price: $0.000000
Shares after: 130,402
Date: 01 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 130,402
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Includes 800 shares acquired on November 14, 2025 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.

Footnote F2

The Stock Appreciation Right is payable in cash, shares of common stock, or a combination thereof, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and the applicable award agreement.

Footnote F3

Vests in three equal annual installments, with the first installment vesting on February 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Footnote F4

Each RSU represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and the applicable award agreement.